Turning gray: the natural history of lung cancer over time.
about
Prognostic factors in resected lung carcinomas.Validation of a blood protein signature for non-small cell lung cancerComparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.Noninvasive risk stratification of lung adenocarcinoma using quantitative computed tomography.SBRT in operable early stage lung cancer patients.Lung cancers diagnosed at annual CT screening: volume doubling timesOptimal sequence of tests for the mediastinal staging of non-small cell lung cancer.Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors.Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)--a pilot study.Cost-Effectiveness Analysis of a Capitated Patient Navigation Program for Medicare Beneficiaries with Lung CancerPatterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly.Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.Preoperative evaluation for lung cancer resection.Phenotyping airway disease with optical coherence tomography.Novel treatment options in stage I non-small-cell lung cancer.Early lung cancer detection by low-dose CT screening: therapeutic implications.Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model.Small median tumor diameter at cure threshold (<20 mm) among aggressive non-small cell lung cancers in male smokers predicts both chest X-ray and CT screening outcomes in a novel simulation framework.Baseline and annual repeat rounds of screening: implications for optimal regimens of screening.[Growth Evaluation of Pulmonary Nodules on Chest CT].Doubling time of thymic epithelial tumours on CT: correlation with histological subtype.Overdiagnosis during lung cancer screening: is it an overemphasised, underappreciated, or tangential issue?[The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer].Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
P2860
Q33697964-C1B1755E-12C3-40A4-AD35-CEA72C28D6DDQ34008245-845011F4-EC04-4281-94FC-B50AE498204CQ34097395-C22704B5-B2DE-4632-97B5-73475DD86CDEQ34623141-669D2374-E1E0-4B4E-9AD1-2D54F777B69AQ35200592-13F0DD30-F91A-417D-9504-6833E878DF6EQ35896730-E963B41C-F224-4969-A623-A568E42A1413Q35905223-589EF30B-6270-4586-8D00-3AEF98CE3932Q36128556-CCFFDC24-75E9-4C37-81BA-161214C9467FQ36406541-9F119291-A83A-42A8-B646-95A0476C7CD5Q36595762-2B63E32B-BE7D-487C-8FAD-5009FDC0B613Q36630997-B121F0E1-F6BC-4953-AB19-8196EBC31FACQ36685679-B7B21B3A-9556-492A-9219-8DE9FFE8358EQ36706735-AC2634BE-EE17-47A0-B17D-B9AA6AE9A350Q36924273-ACE9FBD7-0B03-4469-B709-76608B234B1EQ37552170-3DFA24B2-E4D1-450B-B6D2-BE3F479A5043Q37600536-CD3E6AED-1C68-4D72-900C-FE5F80302FC3Q37663913-0A71C400-2D13-45A7-8CD8-96C77FA5ED5CQ37806308-E66BEA0B-FA2F-4121-97AA-7612155031D4Q38220335-9554DBE3-1779-459B-AC9C-F4D1264A3306Q39049280-55ED1D13-9309-4ABE-8E53-B61B067A6140Q41521258-F7D515C6-81B5-48E6-BCA4-F7CB999D8F97Q42659931-5EA7A083-882F-47D5-A069-D2CD0E4CB6ACQ45007298-FC858A7B-68E2-43DA-8115-7E803AD85697Q49567362-925FAB0C-DAA9-4423-A04A-ACC26D144001Q50268787-7526849E-0F76-425F-9AAF-DE4FD430777EQ50780835-0B06AB7F-B303-4C92-89B3-0A42731DFB65Q53074433-20AB1856-317E-4992-A31F-1AEB53797EE7Q53462930-1776F751-24C2-4FC4-89E3-A0CAAE20D557Q55346824-F466F120-8E9C-4D6D-A178-6DB42A46EFD8
P2860
Turning gray: the natural history of lung cancer over time.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Turning gray: the natural history of lung cancer over time.
@en
Turning gray: the natural history of lung cancer over time.
@nl
type
label
Turning gray: the natural history of lung cancer over time.
@en
Turning gray: the natural history of lung cancer over time.
@nl
prefLabel
Turning gray: the natural history of lung cancer over time.
@en
Turning gray: the natural history of lung cancer over time.
@nl
P1476
Turning gray: the natural history of lung cancer over time.
@en
P2093
Christopher J Gibson
Frank C Detterbeck
P304
P356
10.1097/JTO.0B013E31817C9230
P577
2008-07-01T00:00:00Z